France's Sanofi Q1 revenue rises 13.6% on strong Dupixent sales

Sanofi SA

23/04/2026 06:38

Overview

France pharma group's Q1 revenue rose 13.6% at CER, slightly missing analyst expectations

Business EPS for Q1 grew 14% at CER, driven by pharma launches and Dupixent sales

Company completed Dynavax acquisition and nearly finished €1 bln share buyback

Outlook

Sanofi expects 2026 sales to grow by a high single-digit percentage at CER

Company forecasts 2026 business EPS at CER to grow slightly faster than sales

Sanofi estimates currency impacts at -2% on sales and -3% on business EPS if April 2026 rates persist

Result Drivers

PHARMA LAUNCHES - Co said sales from new pharma products rose 49.6%, led by Ayvakit, ALTUVIIIO, and Sarclisa

DUPIXENT SALES - Dupixent sales grew 30.8% to €4.2 bln, contributing significantly to Q1 growth

ACQUISITION IMPACT - Selling and general expenses rose 11.6%, mainly due to recent acquisitions

Company press release: ID:nGNEc3brJl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Miss*
EUR 10.51 bln
EUR 10.56 bln (10 Analysts)
Q1 EPS
EUR 1.34
Q1 Net Income
EUR 1.61 bln
Q1 Free Cash Flow
EUR 1.05 bln
Q1 Operating Income
EUR 2.97 bln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Sanofi SA is €100.00, about 23.8% above its April 22 closing price of €80.78

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)